Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Intangibles (2019 - 2025)

Revolution Medicines has reported Intangibles over the past 7 years, most recently at $55.8 million for Q4 2025.

  • Quarterly results put Intangibles at $55.8 million for Q4 2025, down 1.54% from a year ago — trailing twelve months through Dec 2025 was $55.8 million (down 1.54% YoY), and the annual figure for FY2025 was $55.8 million, down 1.54%.
  • Intangibles for Q4 2025 was $55.8 million at Revolution Medicines, roughly flat from $55.9 million in the prior quarter.
  • Over the last five years, Intangibles for RVMD hit a ceiling of $63.3 million in Q2 2021 and a floor of $55.8 million in Q1 2021.
  • Median Intangibles over the past 5 years was $58.7 million (2022), compared with a mean of $59.7 million.
  • Biggest five-year swings in Intangibles: increased 13.41% in 2021 and later dropped 11.82% in 2023.
  • Revolution Medicines' Intangibles stood at $63.3 million in 2021, then dropped by 7.07% to $58.8 million in 2022, then dropped by 1.82% to $57.7 million in 2023, then decreased by 1.85% to $56.7 million in 2024, then dropped by 1.54% to $55.8 million in 2025.
  • The last three reported values for Intangibles were $55.8 million (Q4 2025), $55.9 million (Q3 2025), and $55.8 million (Q2 2025) per Business Quant data.